6[2]Campbell Rk.Glimepiride :role of a new sulfonlurea in the treatment of ty pe 2 diabetes[J].Ann Pharmacother,1998,32∶1044-1052．
7[3]Goldberg RB Schneider J, Holvey SM,et al.A dose-response study of gl imepiride in patients with NIDDM who have previously received sulfeonlurea agent s[J].Diabetes Care,1996,19∶849-856.
8[4]Rosenstock J,Samols E,Muchmore DB,et al.The glimepiride Study Group. A new once daily sulfonylurea;double bling,placebo controlled study of NIDDM pat ients[J].Diabetes Care,1996,19∶1194-1199.
9[12]Yu Momose, Kanji Meguro, Hitoshi Ikena, et al. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and relant compounds[J]. Chem Pharm Bull,1991,39(6): 1440-1445.
4Wild S, Roglic G, Green A, et al. Global prevalence of diabetes [J]. Diabetes Care, 2004,27:1047.
5Wu Qi, Zou Lei, Yang Xiuwei, et al. Novel sesquiterpene and coumarin constituents from the whole herbs of Crossostephium chinense[J]. J Asian Nat Prod Res, 2009,11(1) :85.
6Lebrun P, Arkhammar P, Antoine M H, et al. Potent diazoxide analogue activating ATP-sensitive K^ + channels and inhibiting insulin release[ J ]. Diabetologia, 2000,43:723.
7Efanova I B, Zaitsev S V, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic β-cells [ J ]. J Biol Chem, 1998,273(50) :33501.
8Sun A M, Healy G M, Vacek I, et al. Insulin secretion from a continuously subcuhivable isolate derived from foetal bovine pancreata beta cells : I. Monolayer cultures [ J ]. Biochem Biophys Res Commun, 1977 ,79 ( 1 ) : 185.
9Ono J, Takaki R, Okano H, et al. Long-term culture of pancreatic islet ceils with special reference to the β-cell function[J]. In Vitro, 1979,15:95.
10Lambert A E, Blondel B, Kanazawa Y, et al. Monolayer cell culture of neonatal rat pancreas: Light microscopy and evidence for immunoreactive insulin synthesis and release [ J 1. Endoerinol, 1972,90:239.
